Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
Data nadesłania: 29-10-2016
Data ostatniej rewizji: 13-12-2016
Data akceptacji: 14-12-2016
Data publikacji online: 30-12-2016
Data publikacji: 30-12-2016
Reumatologia 2016;54(6):321-325
Hidradenitis suppurativa is a chronic inflammatory disorder characterized by occlusion of the follicular pilosebaceous units of the skin. The treatment options are sometimes very limited and unpleasant odor and abundant drainage complicate the disease. Ankylosing spondylitis is a form of seronegative spondyloarthritis with predominantly axial but also peripheral joint involvement. Both of the conditions lower the patient’s quality of life and affect everyday activities.
We describe a 39-year-old male patient with both diseases treated with different medications with only a modest result. After the initiation of a tumor necrosis factor α (TNF-α) inhibitor (adalimumab) the patient experienced first the musculoskeletal and later on the skin improvement. The introduction of TNF- inhibitors should be considered early in the treatment of overlapping hidradenitis suppurativa and the spondyloarthritis spectrum of conditions. Available medical data confirm the positive results and beneficial effect on disease course, activity and, most importantly, quality of life.
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-644.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions.
J Am Acad Dermatol 1996; 35: 191-194.
Micheletti RG. Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg 2014; 33 (3 Suppl): S48-50.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-998.
Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-839.
Barlev D, Eisen DB, Alikhan A. Hidradenitis suppurativa: a review with a focus on treatment data. Skin Therapy Lett 2015; 20: 1-8.
van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. J Am Acad Dermatol 2015; 73 (5 Suppl 1): S23-S26.
Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2: 9-16.
Fauconier M, Reguiai Z, Colosio A, et al. AB0778 Vespa Study: Association Between Spondyloarthritis and Hidradenitis Suppurativa. Ann Rheum Dis 2015; 74: 1159.
Grassi W, Offidani AM, Blasetti P, et al. HLA-B27 negative ankylosing spondylitis and hidradenitis suppurativa: report of.
a case. Clin Rheumatol 1988; 7: 278-283.
Leybishkis B, Fasseas P, Ryan KF, et al. Hidradenitis suppurativa and acne conglobata associated with spondyloarthropathy. Am J Med Sci 2001; 321: 195-197.
Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis – results from a multicenter national prospective study. J Rheumatol 2014; 41: 490-494.
Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor  therapy. J Clin Rheumatol 2012; 18: 413-415.
Lim DT, James NM, Hassan S, et al. Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases. Curr Rheumatol Rep 2013; 15: 346.
Saraceno R, Babino G, Chiricozzi A, et al. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol 2015; 72: e42-44.
Micheletti RG. An update on the diagnosis and treatment of hidradenitis suppurativa. Cutis 2015; 96 (6 Suppl): 7-12.
Martorell A, García FJ, Jiménez-Gallo D, et al. Update on Hidradenitis Suppurative (Part II): Treatment. Actas Dermosifiliogr 2015; 106: 716-724.
Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord 2016; 17: 343-351.
Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 Suppl 3: iii8-18.
Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-452.
Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol 2015; 73 (5 Suppl 1): S8-11.
van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-, interleukin (IL)-1and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF- and IL-1. Br J Dermatol 2011; 164: 1292-1298.
Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846-855.
Moul DK, Korman NJ. Severe Hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006; 142: 1110-1112.
Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol 2015; 73 (5 Suppl 1):.
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol 2016; 152: 52-59.
Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174: 839-846.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Sotiriou E, Goussi C, Lallas A, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol 2012; 11 (5 Suppl): s15-20.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top